Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 19 min ago
Peer-reviewedCC BYJournal of Obstetrics and Gynaecology

RPL22 mutation is a favourable prognostic subset within mismatch repair-deficient endometrial cancer: a retrospective cohort study

  • Chien-Chi Lu1
  • Wei-Jiun Tang1
  • An-Shine Chao1
  • Chiao-Yun Lin1
  • Ting-Chang Chang1
  • Jung-Erh Yang1
  • Yun-Shien Lee2
  • Chen-Yang Huang3
  • Ren-Chin Wu4
  • Angel Chao1
  • Chyong-Huey Lai1
4 affiliations
  1. 1Department of Obstetrics and Gynaecology, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan
  2. 2Department of Biotechnology, Ming-Chuan University, Taoyuan, Taiwan
  3. 3Department of Medical Oncology, Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan Chang;
  4. 4Department of Anatomical Pathology, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan
Read full textDOICite

Abstract

Background Although mismatch repair-deficient (dMMR) endometrial cancers are highly immunogenic and commonly responsive to immune checkpoint inhibitors, their heterogeneous outcomes indicate that dMMR status alone is insufficient to predict therapeutic benefit. The RPL22 gene – frequently mutated in microsatellite instability-high tumours – represents a candidate biomarker whose prognostic significance in dMMR endometrial cancer remains largely unexplored.Methods In this retrospective cohort study, we analysed 250 patients with immunohistochemically confirmed dMMR endometrial cancer diagnosed between 2008 and 2022. The RPL22 p.K15Rfs*5 mutation was detected by Sanger sequencing and analysed in relation to MMR protein expression pattern, histologic subtype, treatment modality, recurrence pattern, cancer-specific survival (CSS), and progression-free survival (PFS).Results RPL22 mutations were identified in 78.4% (196/250) of dMMR tumours, at a comparable frequency in MLH1-PMS2-deficient (79.2%) and MSH2-MSH6-deficient (76.1%) cases (p = 0.596), and were unrelated to FIGO stage, treatment, or recurrence pattern. RPL22-mutant tumours had significantly better CSS (p < 0.001) and PFS (p = 0.002) than wild-type tumours. MLH1-PMS2-deficient tumours showed worse CSS than MSH2-MSH6-deficient tumours (p = 0.008); within this subgroup, RPL22-mutant tumours had better CSS and PFS than wild-type tumours (p < 0.001 and p = 0.005, respectively). In aggressive histologic subtypes, RPL22 mutations were associated with better CSS (p = 0.003). In multivariable analysis including FIGO stage, RPL22 mutations remained independently associated with better CSS (HR = 0.14; 95% CI, 0.05–0.43; p = 0.001) and PFS (HR = 0.43; 95% CI, 0.23–0.81; p = 0.009).Conclusions In this hypothesis-generating retrospective cohort, the RPL22 p.K15Rfs*5 mutation identified a favourable prognostic subset within dMMR endometrial cancers, particularly among MLH1-PMS2-deficient tumours and aggressive histologic subtypes. Because treatment was not modelled and cancer-specific deaths were few, prospective validation in treatment-annotated cohorts is required before routine clinical implementation.

Related

  1. Exploratory Analysis of Age-Associated Somatic Mutation Patterns and Clinicopathologic Features in Endometrial Cancer
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Extracellular matrix collagen remodeling predicts resistance to immune checkpoint blockade in mismatch repair-deficient endometrial cancer
    Etienne Rouleau, Alexandra Leary, Jakob Nikolas Kather +13
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  3. Apparent diffusion coefficient values on MRI as biomarkers for pre operative prediction of prognostic factors in endometrial cancer
    Ashika Padival, Bijal Manish Patel, Chetana D. Parekh +3
    Gynecologic oncology reportsPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Treatment-Free Interval as a Prognostic Factor for Survival Outcomes in Patients with Advanced or Recurrent Endometrial Cancer Treated with Pembrolizumab Plus Lenvatinib: A Multi-Institutional Real-World Cohort Study
    Chih-Wen Su, Shao-Jing Wang, Yu-Hsiang Shih +9
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  5. Targeted Hotspot Mutation Analysis of KRAS, TP53, and PTEN in Endometrial Cancer Revealed by Next-Generation Sequencing.
    Salar Saadi Hussain, Zahra Abdulqader Amin
    Current oncology (Toronto, Ont.)Peer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsEurope PMC

Cite

BibTeXRIS
BibTeX
@article{lu2026rpl22,
  title = {{RPL22 mutation is a favourable prognostic subset within mismatch repair-deficient endometrial cancer: a retrospective cohort study}},
  author = {Chien-Chi Lu and Wei-Jiun Tang and An-Shine Chao and Chiao-Yun Lin and Ting-Chang Chang and Jung-Erh Yang and Yun-Shien Lee and Chen-Yang Huang and Ren-Chin Wu and Angel Chao and Chyong-Huey Lai},
  journal = {Journal of Obstetrics and Gynaecology},
  year = {2026},
  month = nov,
  doi = {10.1080/01443615.2026.2753612},
  url = {https://doi.org/10.1080/01443615.2026.2753612},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - RPL22 mutation is a favourable prognostic subset within mismatch repair-deficient endometrial cancer: a retrospective cohort study
AU  - Chien-Chi Lu
AU  - Wei-Jiun Tang
AU  - An-Shine Chao
AU  - Chiao-Yun Lin
AU  - Ting-Chang Chang
AU  - Jung-Erh Yang
AU  - Yun-Shien Lee
AU  - Chen-Yang Huang
AU  - Ren-Chin Wu
AU  - Angel Chao
AU  - Chyong-Huey Lai
PY  - 2026
DA  - 2026/11/07
JO  - Journal of Obstetrics and Gynaecology
DO  - 10.1080/01443615.2026.2753612
UR  - https://doi.org/10.1080/01443615.2026.2753612
AB  - Background Although mismatch repair-deficient (dMMR) endometrial cancers are highly immunogenic and commonly responsive to immune checkpoint inhibitors, their heterogeneous outcomes indicate that dMMR status alone is insufficient to predict therapeutic benefit. The RPL22 gene – frequently mutated in microsatellite instability-high tumours – represents a candidate biomarker whose prognostic significance in dMMR endometrial cancer remains largely unexplored.Methods In this retrospective cohort study, we analysed 250 patients with immunohistochemically confirmed dMMR endometrial cancer diagnosed between 2008 and 2022. The RPL22 p.K15Rfs*5 mutation was detected by Sanger sequencing and analysed in relation to MMR protein expression pattern, histologic subtype, treatment modality, recurrence pattern, cancer-specific survival (CSS), and progression-free survival (PFS).Results RPL22 mutations were identified in 78.4% (196/250) of dMMR tumours, at a comparable frequency in MLH1-PMS2-deficient (79.2%) and MSH2-MSH6-deficient (76.1%) cases (p = 0.596), and were unrelated to FIGO stage, treatment, or recurrence pattern. RPL22-mutant tumours had significantly better CSS (p < 0.001) and PFS (p = 0.002) than wild-type tumours. MLH1-PMS2-deficient tumours showed worse CSS than MSH2-MSH6-deficient tumours (p = 0.008); within this subgroup, RPL22-mutant tumours had better CSS and PFS than wild-type tumours (p < 0.001 and p = 0.005, respectively). In aggressive histologic subtypes, RPL22 mutations were associated with better CSS (p = 0.003). In multivariable analysis including FIGO stage, RPL22 mutations remained independently associated with better CSS (HR = 0.14; 95% CI, 0.05–0.43; p = 0.001) and PFS (HR = 0.43; 95% CI, 0.23–0.81; p = 0.009).Conclusions In this hypothesis-generating retrospective cohort, the RPL22 p.K15Rfs*5 mutation identified a favourable prognostic subset within dMMR endometrial cancers, particularly among MLH1-PMS2-deficient tumours and aggressive histologic subtypes. Because treatment was not modelled and cancer-specific deaths were few, prospective validation in treatment-annotated cohorts is required before routine clinical implementation.
SN  - 1364-6893
SN  - 0144-3615
ER  -